Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Tumor Immunotherapy01:27

Tumor Immunotherapy

659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Chronic low-dose iron exposure induces GPX4-mediated resistance to ferroptosis in a human chondrocyte cell line.

Cell and tissue research·2026
Same author

Elevated Circulating Follistatin Is Associated With Diabetic Status and Glycemic Dysregulation in Patients With β-Thalassemia Major.

Cell biochemistry and function·2026
Same author

Short-Chain Fatty Acids Modulate Iron Metabolism and Induce Oxidative Stress and Ferroptosis in Breast Cancer Cells.

Journal of biochemical and molecular toxicology·2026
Same author

Estrogen-Induced Hypermethylation Silencing of <i>RPS2</i> and <i>TMEM177</i> Inhibits Energy Metabolism and Reduces the Survival of CRC Cells.

Cells·2026
Same author

Modulation of hepcidin synthesis: the core link in the bi-directional relationship between iron and obesity.

Reviews in endocrine & metabolic disorders·2025
Same author

Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets.

Hepatology international·2025

Video Experimental Relacionado

Updated: Sep 9, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

TIGIT en el cáncer: desde el mecanismo de acción hasta estrategias inmunoterapéuticas prometedoras

Haozhe Cui1, Mawieh Hamad2, Eyad Elkord3,4

  • 1Department of Biosciences and Bioinformatics & Suzhou Municipal Key Lab of Biomedical Sciences and Translational Immunology, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, Jiangsu, China.

Cell death & disease
|September 1, 2025
PubMed
Resumen
Este resumen es generado por máquina.

El punto de control inmune TIGIT inhibe la actividad de las células T y NK. Se están explorando nuevas terapias combinadas y enfoques alternativos debido a las limitaciones con la monoterapia de anticuerpos anti-TIGIT en ensayos clínicos.

Más Videos Relacionados

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

670
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

670
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K

Área de la Ciencia:

  • Inmunología
  • Biología del cáncer
  • Desarrollo de drogas

Sus antecedentes:

  • TIGIT (inmunorreceptor de células T con dominios Ig y ITIM) es una proteína de punto de control inmune.
  • Inhibe las funciones citotóxicas de las células T y NK a través de varios mecanismos.
  • TIGIT pertenece a la familia de proteínas tipo PVR e interactúa con CD155.

Objetivo del estudio:

  • Revisar los mecanismos de supresión inmune mediada por la TIGIT.
  • Discutir las estrategias inmunoterapéuticas emergentes dirigidas a la TIGIT.
  • Proporcionar una visión general de los ensayos clínicos actuales y las direcciones futuras para las terapias basadas en TIGIT.

Principales métodos:

  • Revisión de la literatura sobre la función de la TIGIT y las estrategias terapéuticas.
  • Análisis de los datos de ensayos preclínicos y clínicos para las terapias anti-TIGIT.
  • Discusión de enfoques alternativos más allá de los anticuerpos monoclonales.

Principales resultados:

  • TIGIT inhibe la inmunidad antitumoral al suprimir la actividad de las células T y NK.
  • La monoterapia con anticuerpos monoclonales contra el TIGI ha mostrado un éxito clínico limitado.
  • Las terapias combinadas y las estrategias alternativas como los inhibidores de moléculas pequeñas y las células CAR-T son prometedoras.

Conclusiones:

  • Comprender los complejos mecanismos inhibidores de la TIGIT es crucial.
  • Las inmunoterapias combinadas dirigidas a la TIGIT ofrecen una vía prometedora para el tratamiento del cáncer.
  • Se justifica una mayor investigación sobre estrategias alternativas de orientación de TIGIT para superar las limitaciones actuales.